EUVIMEDEUVIMED entdecken
Crossref

Relaxin‐2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling

Lankai Yi, Ning Han, Zhong Li, Housen Jiang, Zhenhao Cao iD

Biotechnology and Applied Biochemistry · 2025

DOI: 10.1002/bab.2661 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2025. Verfasst von Lankai Yi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hand, Foot, and Orthopedics Surgery, Weifang People's Hospital, Weifang, Shandong Province, China. Hauptthemen laut MEDLINE: Osteoblasts, ErbB Receptors, Cell Differentiation, Signal Transduction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Weifang Health Commission Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Loss of osteogenic differentiation potential of osteoblasts has been associated with the pathogenesis of osteoporosis. Thus, stimulation of osteoblastic differentiation is a therapeutic strategy for osteoporosis. Relaxin‐2 is a peptide hormone with potent biological functions. However, the effects of Relaxin‐2 in osteoblastic differentiation and osteoporosis have not been reported before. Here, we report a novel physiological role of Relaxin‐2 in promoting osteoblastic differentiation and mineralization of MC3T3‐E1 cells. Our results indicate that exposure to Relaxin‐2 upregulated the expression, and elevated the activity of alkaline phosphatase (ALP) when MC3T3‐E1 cells were cultured in osteogenic differentiation medium (OM). Additionally, Relaxin‐2 upregulated the mRNA levels of osteocalcin ( ocn ), osteopontin ( opn ), and collagen type I alpha 1 ( Col1a1 ). The alizarin red S staining assay revealed that Relaxin‐2 promoted the mineralization of MC3T3‐E1 cells. We also found that Relaxin‐2 increased the expression of Runx‐2 as well as the epidermal growth factor ( EGF ) and epidermal growth factor receptor ( EGFR ). Importantly, silencing of EGF abolished the effects of Relaxin‐2 in osteoblastic differentiation and related gene expression. These findings suggest that Relaxin‐2 stimulates osteogenic differentiation through activating EGF/EGFR signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoblastsErbB ReceptorsCell DifferentiationSignal TransductionRelaxinEpidermal Growth FactorMiceAnimalsOsteogenesisCell Line

Stichwörter der Autor:innen

EGFRunx‐2osteoblastic differentiationosteoporosis

Substanzen

ErbB ReceptorsRelaxinEpidermal Growth FactorEGFR protein, mouse

Autor:innen und Institutionen

  • Department of Hand, Foot, and Orthopedics Surgery, Weifang People's Hospital, Weifang, Shandong Province, China.

ORCID-Profile: Zhenhao Cao

Förderung

  • Weifang Health Commission Research Project

Zitieren

APA

Yi, L., Han, N., Li, Z., Jiang, H., & Cao, Z. (2025). Relaxin‐2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2661

Vancouver

Yi L, Han N, Li Z, Jiang H, Cao Z. Relaxin‐2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.2661

BibTeX
@article{Yi2025,
  author = {Yi, Lankai and Han, Ning and Li, Zhong and Jiang, Housen and Cao, Zhenhao},
  title = {Relaxin‐2 promotes osteoblastic differentiation mediated by epidermal growth factor and epidermal growth factor receptor signaling},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2025},
  doi = {10.1002/bab.2661}
}
Kostenlos starten →